List view / Grid view
What if vaccines could train your immune system to eliminate infections at the source? Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity - providing a precise and durable defence against complex infectious diseases.
New research reveals how B cells balance mutation and clonal expansion to refine their antibodies. This discovery could lead to more targeted and effective vaccine designs for various diseases.
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
Researchers at Washington University are developing a vaccine using nanofiber technology to prevent dementia, offering a safer and more effective alternative to current treatments.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
A new protein-based nanoparticle vaccine protected mice against a variety of coronaviruses, researchers have shown.
